<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620646</url>
  </required_header>
  <id_info>
    <org_study_id>2006-12-026</org_study_id>
    <nct_id>NCT00620646</nct_id>
  </id_info>
  <brief_title>The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol</brief_title>
  <acronym>4C-DES</acronym>
  <official_title>The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of increased dosing of clopidogrel and adding cilostazol to standard&#xD;
      dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel&#xD;
      resistance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using dual antiplatelet agents with aspirin and clopidogrel is essential after drug-eluting&#xD;
      stent implantation to prevent restenosis and stent thrombosis. However, variable platelet&#xD;
      response and potential resistance to therapy have emerged with clopidogrel. Several studies&#xD;
      showed that clopidogrel resistance is associated with increased cardiovascular events after&#xD;
      coronary interventions. New antiplatelet therapeutic strategy of is needed in case of&#xD;
      clopidogrel resistance. We started this study to compare the effect of double dosing of&#xD;
      clopidogrel to 150mg per day and adding cilostazol to standard dose of clopidogrel after the&#xD;
      insertion of drug-eluting stent in patients with clopidogrel resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% platelet inhibition with VeryfyNow-P2Y12 assay, platelet function test</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>P2Y12 reaction unit (PRU)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Clopidogrel Non-Responsiveness</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin plus increasing clopidogrel group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin, clopidogrel plus cilostazol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin, clopidogrel</intervention_name>
    <description>aspirin 100 mg plus clopidogrel 150mg qd</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin, clopidogrel, cilostazol</intervention_name>
    <description>aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with clopidogrel resistance with treatment of dual antiplatelet agent, aspirin&#xD;
             and clopidogrel, for more than 4 weeks after drug-eluting stent&#xD;
&#xD;
          -  Clopidogrel resistance is defined as a patients with platelet inhibition less than 30%&#xD;
             in platelet function test(VerifyNow-P2Y12 assayTM, Accumetrics, San Diego, CA, USA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction within 2 weeks&#xD;
&#xD;
          -  Unstable angina within 2 weeks&#xD;
&#xD;
          -  History of using glycoprotein IIb/IIIa inhibitor within 1 month&#xD;
&#xD;
          -  Cerebral infarction within 3 months&#xD;
&#xD;
          -  Bleeding diathesis like coagulation disorder, thrombocytopenia (platelet count &lt;&#xD;
             100,000/uL)&#xD;
&#xD;
          -  history of gastrointestinal bleeding or genitourinary bleeding within 3 months&#xD;
&#xD;
          -  needed oral anticoagulation&#xD;
&#xD;
          -  aspirin, clopidogrel or cilostazol hypersensitivity&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  serum creatinine level &gt;2mg/dl&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  using cytochrome P450 inhibitor (eg, itraconazole)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>January 27, 2008</study_first_submitted>
  <study_first_submitted_qc>February 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>HC Gwon</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>clopidogrel</keyword>
  <keyword>platelets</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

